- The novel psoriatic microenvironment (PME) score, based on expression values of 33 genes, is associated with clinical response in patients with psoriasis receiving systemic treatment.
Why this matters
- The PME score predicts response to therapy before apparent clinical changes.
- High PME score, characterized by keratinocyte differentiation, was associated with better treatment response (75.8% improvement in Psoriasis Area and Severity Index [PASI]; P=.03).
- Low PME score, characterized by an immune activation signature, was associated with worse treatment response (53.5% improvement in PASI; P=.03).
- PME score correlated with responder status up to 8 weeks earlier than PASI reduction in patients treated with etanercept, methotrexate plus adalimumab, or tofacitinib.
- 1145 skin samples from 12 retrospective psoriasis studies were analyzed.
- Funding: National Institute of Arthritis and Musculoskeletal and Skin Diseases.
- Retrospective analysis.